341 related articles for article (PubMed ID: 10797281)
21. Epidermal growth factor receptor coexpression modulates susceptibility to Herceptin in HER2/neu overexpressing breast cancer cells via specific erbB-receptor interaction and activation.
Diermeier S; Horváth G; Knuechel-Clarke R; Hofstaedter F; Szöllosi J; Brockhoff G
Exp Cell Res; 2005 Apr; 304(2):604-19. PubMed ID: 15748904
[TBL] [Abstract][Full Text] [Related]
22. Stimulation of beta1-integrin function by epidermal growth factor and heregulin-beta has distinct requirements for erbB2 but a similar dependence on phosphoinositide 3-OH kinase.
Adelsman MA; McCarthy JB; Shimizu Y
Mol Biol Cell; 1999 Sep; 10(9):2861-78. PubMed ID: 10473632
[TBL] [Abstract][Full Text] [Related]
23. ErbB Receptors and Cancer.
Wang Z
Methods Mol Biol; 2017; 1652():3-35. PubMed ID: 28791631
[TBL] [Abstract][Full Text] [Related]
24. Protein-tyrosine phosphatase PTPN9 negatively regulates ErbB2 and epidermal growth factor receptor signaling in breast cancer cells.
Yuan T; Wang Y; Zhao ZJ; Gu H
J Biol Chem; 2010 May; 285(20):14861-14870. PubMed ID: 20335174
[TBL] [Abstract][Full Text] [Related]
25. Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2)-overexpressing breast cancer cells in vitro and in vivo.
Moulder SL; Yakes FM; Muthuswamy SK; Bianco R; Simpson JF; Arteaga CL
Cancer Res; 2001 Dec; 61(24):8887-95. PubMed ID: 11751413
[TBL] [Abstract][Full Text] [Related]
26. Phosphatidylinositol 3-kinase recruitment by p185erbB-2 and erbB-3 is potently induced by neu differentiation factor/heregulin during mitogenesis and is constitutively elevated in growth factor-independent breast carcinoma cells with c-erbB-2 gene amplification.
Ram TG; Ethier SP
Cell Growth Differ; 1996 May; 7(5):551-61. PubMed ID: 8732665
[TBL] [Abstract][Full Text] [Related]
27. Overexpression of ErbB2 receptor inhibits IGF-I-induced Shc-MAPK signaling pathway in breast cancer cells.
Lu Y; Zi X; Zhao Y; Pollak M
Biochem Biophys Res Commun; 2004 Jan; 313(3):709-15. PubMed ID: 14697248
[TBL] [Abstract][Full Text] [Related]
28. Identification of epidermal growth factor receptor and c-erbB2 pathway inhibitors by correlation with gene expression patterns.
Wosikowski K; Schuurhuis D; Johnson K; Paull KD; Myers TG; Weinstein JN; Bates SE
J Natl Cancer Inst; 1997 Oct; 89(20):1505-15. PubMed ID: 9337347
[TBL] [Abstract][Full Text] [Related]
29. The relative role of ErbB1-4 receptor tyrosine kinases in radiation signal transduction responses of human carcinoma cells.
Bowers G; Reardon D; Hewitt T; Dent P; Mikkelsen RB; Valerie K; Lammering G; Amir C; Schmidt-Ullrich RK
Oncogene; 2001 Mar; 20(11):1388-97. PubMed ID: 11313882
[TBL] [Abstract][Full Text] [Related]
30. Essential role for Rac in heregulin beta1 mitogenic signaling: a mechanism that involves epidermal growth factor receptor and is independent of ErbB4.
Yang C; Liu Y; Lemmon MA; Kazanietz MG
Mol Cell Biol; 2006 Feb; 26(3):831-42. PubMed ID: 16428439
[TBL] [Abstract][Full Text] [Related]
31. Adenovirus-mediated overexpression of dominant negative epidermal growth factor receptor-CD533 as a gene therapeutic approach radiosensitizes human carcinoma and malignant glioma cells.
Lammering G; Lin PS; Contessa JN; Hampton JL; Valerie K; Schmidt-Ullrich RK
Int J Radiat Oncol Biol Phys; 2001 Nov; 51(3):775-84. PubMed ID: 11697324
[TBL] [Abstract][Full Text] [Related]
32. The neuregulin-I/ErbB signaling system in development and disease.
Britsch S
Adv Anat Embryol Cell Biol; 2007; 190():1-65. PubMed ID: 17432114
[TBL] [Abstract][Full Text] [Related]
33. Ligand discrimination in signaling through an ErbB4 receptor homodimer.
Sweeney C; Lai C; Riese DJ; Diamonti AJ; Cantley LC; Carraway KL
J Biol Chem; 2000 Jun; 275(26):19803-7. PubMed ID: 10867024
[TBL] [Abstract][Full Text] [Related]
34. Binding specificities and affinities of egf domains for ErbB receptors.
Jones JT; Akita RW; Sliwkowski MX
FEBS Lett; 1999 Mar; 447(2-3):227-31. PubMed ID: 10214951
[TBL] [Abstract][Full Text] [Related]
35. ZD1839 (IRESSA), an EGFR-selective tyrosine kinase inhibitor, enhances taxane activity in bcl-2 overexpressing, multidrug-resistant MCF-7 ADR human breast cancer cells.
Ciardiello F; Caputo R; Borriello G; Del Bufalo D; Biroccio A; Zupi G; Bianco AR; Tortora G
Int J Cancer; 2002 Mar; 98(3):463-9. PubMed ID: 11920601
[TBL] [Abstract][Full Text] [Related]
36. Expression of bone morphogenetic protein 6 in normal mammary tissue and breast cancer cell lines and its regulation by epidermal growth factor.
Clement JH; Sänger J; Höffken K
Int J Cancer; 1999 Jan; 80(2):250-6. PubMed ID: 9935207
[TBL] [Abstract][Full Text] [Related]
37. Neuregulin-1 only induces trans-phosphorylation between ErbB receptor heterodimer partners.
Li Z; Mei Y; Liu X; Zhou M
Cell Signal; 2007 Mar; 19(3):466-71. PubMed ID: 16978839
[TBL] [Abstract][Full Text] [Related]
38. Co-expression of epidermal growth factor receptor and transforming growth factor-alpha predicts worse prognosis in breast-cancer patients.
Umekita Y; Ohi Y; Sagara Y; Yoshida H
Int J Cancer; 2000 Nov; 89(6):484-7. PubMed ID: 11102891
[TBL] [Abstract][Full Text] [Related]
39. [Relation between c-erbB1, c-erbB2, MAPK expression and resistance to tamoxifen in breast cancer cells in vitro].
Zhang QY; Zhao WH; Kang XM
Zhonghua Zhong Liu Za Zhi; 2006 Nov; 28(11):826-30. PubMed ID: 17416003
[TBL] [Abstract][Full Text] [Related]
40. Controlled dimerization of ErbB receptors provides evidence for differential signaling by homo- and heterodimers.
Muthuswamy SK; Gilman M; Brugge JS
Mol Cell Biol; 1999 Oct; 19(10):6845-57. PubMed ID: 10490623
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]